Tablet: 450 mg

CMV retinitis treatment:

900 mg orally twice a day for 2–4 weeks

CMV colitis or oesophagitis

Valganciclovir may be considered if symptoms are not severe enough to prevent oral absorption (not licensed)

CMV retinitis maintenance:

900 mg orally once a day

Myelosuppression – neutropenia, thrombocytopenia; rash; CNS effects including fitting, confusion, anxiety; abnormal LFTs; psychological effects including depression

Additive toxicity with other myelosuppressive drugs e.g. cotrimoxazole, zidovudine, and trimetrexate

Didanosine increases plasma concentrations; probenecid delays renal excretion

Dose in renal impairment GFR (ml/min)

40–59:induction/treatment 450 mg twice a day

Maintenance/prophylaxis 450 mg daily

25–39:Induction/treatment 450 mg daily every 24 hours

Maintenance/prophylaxis 450 mg every 48 hours

10–24: induction/treatment 450 mg every 48 hours

Maintenance/prophylaxis 450 mg twice weekly

<10: Avoid

No data in patients with hepatic impairment

Compatible – Maternal Benefit >> Embryo-Foetal Risk